


WHO/MPP mRNA Technology Transfer Programme

1	Afrigen	mRNA HUB
	Biovac	1st spoke
2	Biovax	
3	Bio-Manguinhos	
4	Biofarma	
5	BiologicalE	
6	BioGeneric Pharma	
7	Biovaccines Nigeria	
8	Darnitsa	
9	Incepta Vaccine	
10	Institute Pasteur de Dakar	
11	Institute Pasteur de Tunis	
12	Institute Torlak	
13	National Institute of Health	
14	Polyvac	
15	Sinergium Biotech	




- **Aim** – build mRNA vaccine manufacturing capacity in LMICs to ensure regional response to future pandemic
- **Cape Town meeting, April 2023:**
Establishing mRNA manufacturing capacity is not sufficient In absence of routine manufacturing activity these facilities will not be sustainable

Towards establishing R&D consortia

- R&D **regional collaborative** approach
 - Regional PH problem/market and set of key stakeholders
- Identify **mRNA products** that are commercially viable
 - Based on country needs
 - PTRS/PPDP evaluation
- Identify **R&D centers** to drive mRNA product development
 - Identify key R&D collaborators (e.g. academics, translational)
 - Recognizing that manufacturers have limited R&D capacity
- **Bangkok scientific consultation, October 2023**
 - Dengue, HFMD, Tx HPV, *P. vivax*
 - Establish consortia to drive mRNA product development
 - **IVI** (dengue), **Hilleman** (HFMD), **Chula VRC** (HPV), **Mahidol** (*P. vivax*)
- Replicate the model in other WHO regions

SEARO/WPRO	
Dengue	Nipah
HPV (Tx)	Rabies
Malaria (<i>P. vivax</i>)	Rotavirus
HFMD	Flu



R&D consortia – High-level Considerations

- **Consortium Goal** - develop commercially viable mRNA products that can be manufactured by the WHO/MPP mRNA manufacturing partners
 - Evidence-based product development up to proof-of-concept early clinical trial and transfer to manufacturing partners for further development
 - Locally owned
 - Consortia leads identify partners and responsible for resource mobilization
 - Not WHO/MPP TT programme, but WHO/MPP to support as needed
- Ensure **ACCESS** to all WHO/MPP partners.
 - Technology should be made available to all partners
 - Reasonable royalties not a barrier.
 - Open to innovations
 - Compatibility with Afrigen process
 - Sharing/access to technology for candidate vaccines should permit recipients to adapt to their manufacturing process/technology
 - **Singapore Declaration of Commitment**

